# The Toadstool Week In Review
## Week Ending May 15, 2026

Well friends, this has been quite a week in the sub-$5 universe, and we need to start with something genuinely rare and worth your attention: a bona fide shell-to-operating-company transformation. Forian Inc. (FORA) completed its reverse merger with 2025 Acquisition Company this week, with shareholders tendering their shares at $2.17 per share in cash—and here's the kicker, roughly 91% of outstanding shares came in, meaning this deal had real conviction behind it. This isn't just another SPAC shuffle; this is a blank-check company finally fulfilling its purpose by merging with an actual business. If you've been watching the small-cap space, you know these moments matter because they signal that capital is willing to put real money behind real operations, not just hope and ticker symbols. Keep an eye on how this one trades once the dust settles—reverse merger completions often create interesting opportunities for patient investors.

The broader M&A action was robust this week beyond Forian. We saw Enhanced Group Inc. (formerly A Paradise Acquisition Corp.) domesticate from the British Virgin Islands and complete its business combination, PMGC Holdings acquired A&B Aerospace for roughly $4.5 million in cash, and perhaps most notably, Udemy merged into Coursera with shareholders receiving 0.8 shares of Coursera stock for each Udemy share—a move that pulled Udemy out of our under-$5 sandbox entirely. These transactions tell a story: consolidation is happening, and the small-cap world is being reorganized by deals both big and small. It's the kind of week where refresh your watchlists because yesterday's stock might be today's delisted subsidiary.

On the technical side, we logged an impressive roster of EMA crossovers this week, with 17 stocks signaling potential momentum shifts on the 50-day moving average cross. Leslie's (LESL) absolutely exploded with volume of over 41 million shares—more than 300 times its 50-day average—suggesting something material grabbed attention there. Peraso (PRSO) and Coherus Oncology (CHRS) also saw heavy volume spikes alongside their crossovers. What's interesting is the breadth: we're seeing action across biotech (Lantern Pharma, Coya Therapeutics, MacroGenics), retail and services (Leslie's, Dogwood), and gaming (PlayStudios). When crossovers light up across this many different sectors in a single week, it usually means there's underlying buying interest in the small-cap space more broadly, not just sector-specific rotation.

The earnings calendar kept humming along with Q1 2026 results rolling in steadily. Knightscope reported Q1 revenue up 106% to $6 million, which is exactly the kind of growth story that gets attention in this corner of the market. Lantern Pharma, Expion360, SELLAS Life Sciences (which popped 50.5% after pivotal AML trial progress), and a dozen others reported quarterly numbers. While individual results varied wildly—as they do in small-cap land—the sheer volume of earnings tells us that real companies with real revenue are trading in this space, not just concept plays. That's healthy.

One final note: we saw some housekeeping action too, including Aditxt's 1-for-27 reverse stock split this week and a few leadership transitions (like Anavex's COO departure). These kinds of corporate actions tend to precede bigger moves, so watch the companies taking restructuring steps—sometimes the market is pricing in change before it's fully announced.

**Looking Ahead:** Keep your eyes on earnings releases coming through the following week, particularly from any companies that reported crossover signals this week. The unusual volume on Leslie's and Peraso warrants watching to see if there's follow-through buying or if it was a one-day event. And if you've been sitting on the sidelines waiting for deal activity, this week proved the M&A appetite remains solid—stay alert to reverse merger completions, which often create brief windows of trading opportunity. Also worth noting: we've got a few recent graduates now trading above $5 (hello, AIOS at $16.17 and Immunic at $12.65), so it's nice to see some of our under-$5 universe actually graduating to better-capitalized status.

*This commentary is for informational and educational purposes only and is not investment advice. Past performance does not guarantee future results. Always conduct your own due diligence and consult with a qualified financial advisor before making any investment decisions.*